Media Coverage header image

Media Coverage

Advanced Search
  • 06172026
    Clinical Laboratory Products

    Over the past year, Alzheimer’s blood testing has moved from research into clinical practice. Since May 2025, the field has seen its first US Food and Drug Administration (FDA)-cleared blood test and its first clinical practice guideline for blood-based biomarkers. Blood testing may also reduce the number of patients referred for amyloid PET imaging. Michael Racke, MD, medical director of neurology at Quest Diagnostics, points to research he co-authored suggesting that a blood test measuring amyloid beta 42 and 40 proteins (Aβ42/40) could reduce PET scan evaluations by about 40% by helping rule out Alzheimer’s disease as the cause of mild cognitive impairment. “Ruling out Alzheimer’s disease can prompt investigation of non-Alzheimer’s disease causes of mild cognitive impairment or dementia. When patients receive the right care at the right time, unnecessary costs may be reduced,” Racke says.

  • 06082026
    Dayton Daily News

    Chronic medical issues are frustrating for both doctors and patients, who just want to feel better. Tammie Robie, 51, struggled for nearly 20 years with blood pressure that was resistant against multiple medications. She pushed through her days as a wife, mother, teacher and competitive runner. Dr. Sanjay Dixit, the medical director for Quest Diagnostics, said PA was considered uncommon for many years. “Primary aldosteronism occurs when the adrenal glands produce too much aldosterone, a hormone that helps regulate sodium and potassium in the blood,” he said. The adrenal glands are located on top of the kidneys. According to Dixit, the Endocrine Society recommended in 2025 that all patients with hypertension be evaluated for PA. He notes that nearly half of all adults, or nearly 120 million people, have high blood pressure.

  • 05282026
    Parents

    Postpartum body odor and sweating are common and generally not a cause for concern. Hormonal changes, milk production, and excess fluid shedding contribute to postpartum body odor. Damian Pat Alagia III, MD, MS, MBA, medical director for women’s health at Quest Diagnostics, explains that a pregnant person gains up to 10 pounds of amniotic fluid, blood, and other fluids.“Once the baby is born, the fluid needs somewhere to go," Dr. Alagia adds. Because of this, postpartum parents often experience increased sweating. "This is the body’s way of flushing out these excess fluids.”

  • 05182026
    KevinMD

    Primary aldosteronism (PA) is a serious condition that affects as many as 5 to 10 percent of adults with high blood pressure (BP). High BP is widely prevalent in the U.S., nearly half of all adults (almost 120 million individuals) have it. Yet, for many years, PA was considered uncommon. However, recent research shows PA is both prevalent and under-detected. Untreated, it significantly raises risk of heart attack, stroke, and kidney disease.

  • 05052026
    Medical Laboratory Observer

    Alzheimer’s disease (AD) is the major cause of dementia worldwide that leads to morbidity, long term care utilization, and significant healthcare costs. Dr. Yonghong Li and his colleagues at Quest Diagnostics performed a study to determine the efficacy and cost-effectiveness of using blood-based biomarker as a triage in Alzheimer’s disease testing. Dr. Michael K. Racke, Medical Director of Neurology at Quest Diagnostics and a co-investigator of this study summarized their findings.

  • 05022026
    Oncology Times

    Early cancer detection once meant imaging, pathology, and a defined set of screening tests with established follow-up pathways. Today, circulating tumor DNA assays, minimal residual disease (MRD) testing, and multi-cancer early detection platforms are expanding what is possible, often faster than the health systems meant to operationalize them.Yuri Fesko, MD, Senior Vice President and Chief Medical Officer for Quest Diagnostics, sees both extraordinary promise and practical disconnect.

  • 04232026
    The WHOOP Podcast

    In this episode of the WHOOP Podcast, WHOOP Founder and CEO Will Ahmed sits down with Quest Diagnostics CEO Jim Davis to discuss the partnership behind WHOOP Advanced Labs. Will and Jim discuss how combining blood biomarkers with continuous physiological data is reshaping consumer health.

  • 04222026
    Clinical Laboratory Products

    City of Hope is implementing the Haystack minimal residual disease (MRD) test from Quest Diagnostics for clinical trial participants with solid tumor cancers. The research aims to guide disease management for patients with breast, colorectal, ovarian, and prostate cancer.

  • 04212026
    Reuters

    Quest Diagnostics on Tuesday raised its forecast for 2026 profit and revenue after posting first-quarter results above Wall Street estimates, citing resilient demand for routine diagnostic testing. Shares of the ​New Jersey-based company were up about 4% in early trading.

  • 04162026
    CBS News Baltimore (WJZ-TV)

    A blood test based from a South Baltimore lab is making treatment clearer for cancer patients. HaystackMRD, made by Haystack Oncology within Quest Diagnostics, looks for signs of cancer that conventional methods may miss. While it's been in development for many, many years, the test was made clinically available for oncologists and pharmaceutical partners in late 2024.

  • 04062026
    Medical Laboratory Observer

    In this exclusive interview, Quest Diagnostics’ Ines Dahne-Steuber discusses their daytime kidney care lab strategy with MLO Editor in Chief, Christina Wichmann.

  • 03272026
    Today's Clinical Lab

    Per- and polyfluorinated alkyl substances, or PFAS, are known by many as “forever chemicals” due to the way they can accumulate and linger in the environment and body. These chemicals are widely used in thousands of industrial and consumer products and may enter the body through contaminated food and water. Research by Quest Diagnostics outlined similar results: men that were tested using the company’s PFAS blood test had higher PFAS concentrations in their blood than women who were tested.

  • 03192026
    Becker's ASC Review

    Helio Genomics and Quest Diagnostics have partnered to expand access to a blood-based liver cancer test across the U.S. Starting in April, providers with a Quest account will be able to order HelioLiver, a test designed for early detection of hepatocellular carcinoma, through Quest’s network, according to a March 18 news release shared with Becker’s.

  • 03112026
    Clinical Laboratory Products

    Guardant Health’s Shield blood-based colorectal cancer screening test is now available for physician ordering through Quest Diagnostics’ nationwide network, the companies announced March 10, giving clinicians a new avenue to access the only blood test with full Food and Drug Administration approval as a primary colorectal cancer (CRC) screening option for average-risk adults aged 45 and older.

  • 03052026
    Healthcare Finance News

    Several large healthcare organizations have announced they have signed on to Google Cloud for Gemini-powered AI agents for patient engagement, improved workflows, revenue cycle capabilities and easier-to-read lab results. At HIMSS26, Google Cloud will show how agentic AI can lead healthcare organizations from siloed data entry to automated results. Quest Diagnostics, which offers diagnostic information services, has announced Quest AI Companion, a new AI-powered chat feature that helps individuals understand Quest laboratory test results. Through the app and portal MyQuest, individuals can ask questions about their test results and receive explanations in a HIPAA-compliant solution.

  • 03022026
    Fierce Biotech

    Quest Diagnostics is launching a chatbot tailored for laboratory test results as it seeks to allow patients the ability to come to terms with their findings and perform deeper dives on their own health. The Quest AI Companion can probe data from patients’ labs for up to five years in order “to help explain results and uncover potential health risks,” according to a March 2 statement.

  • 02272026
    ROI-NJ

    Quest Diagnostics, a leading provider of diagnostic information services with headquarters in Secaucus, announced that Benjamin Beauvalot has joined the company as senior vice president, chief strategy and M&A officer. “Ben has an extensive track record of delivering successful growth, M&A and transformation strategies for world-class health care organizations,” Davis said.

  • 02172026
    Rare Cancer

    Quest Diagnostics said its Flow Cytometry MRD for Myeloma test detects minimal residual disease (MRD), the small number of cancer cells that can remain in the body after treatment and potentially lead to relapse, “at a fraction of the cost” of other methods. “Our Flow Cytometry MRD for Myeloma test harnesses cutting-edge science and technology to deliver ultrasensitive insights from a noninvasive blood test, thereby improving care and value for patients and the healthcare system,” Yuri Fesko, MD, Quest’s senior vice president and chief medical officer, said in a company press release.

  • 02132026
    Physician's Weekly

    In 2020, as many as 5.8 million Americans were living with Alzheimer’s Disease (AD)—a number projected to nearly triple to 14 million people by 2060.1 As changes in the brain can begin years before the first symptoms appear, the science around assessing risk and diagnosing AD and other dementias is complex and continues to evolve with the publication of new research. (By Michael K. Racke, MD)

  • 02102026
    360Dx

    Quest Diagnostics reported Tuesday a 7 percent year-over-year increase in its Q4 2025 revenue. Revenue for the three months ended Dec. 31, 2025, was $2.81 billion, up from $2.62 billion in the same quarter last year and above the consensus Wall Street estimate of $2.76 billion. Requisition volumes rose 9 percent during the quarter while revenue per requisition fell less than 1 percent. Organic requisition volume rose 8 percent year over year, the Secaucus, New Jersey-based company said.

  • 02092026
    Boston 25 (WFXT-TV)

    Forever chemicals. They’re everywhere — from non-stick pans to seafood to cosmetics. 25 Investigates worked with Quest Diagnostics, which offers a PFAS blood panel that screens for nine common forever chemicals for $350. Quest allowed us to film most of my blood test. We went in before the lab opened one January morning to protect patient privacy. Kavanaugh found the test itself to be quick and painless — just one vial of blood. Quest says it began offering the PFAS blood test in 2024. Quest says theirs is the first PFAS blood test available as a consumer-initiated test with physician oversight based on recommendations by the National Academies of Sciences, Engineering, and Medicine (NASEM).

  • 02032026
    Fierce Biotech

    Quest Diagnostics has rolled out an ultrasensitive blood test to monitor multiple myeloma treatment, potentially sparing patients from more invasive and costly bone marrow aspirations.

  • 01292026
    Value Health Voices

    Quest Diagnostics CMO Dr. Yuri Fesko joins Value Health Voices to decode the Clinical Laboratory Fee Schedule, the impact of PAMA and SALSA, and the future of precision medicine.

  • 01202026
    360Dx

    As Quest Diagnostics President and CEO Jim Davis noted at the 44th Annual JP Morgan Healthcare Conference last week, the RESULTS Act still needed to go through markup in a House subcommittee, then receive consideration in the Senate, undergo a technical feasibility assessment by the US Centers for Medicare and Medicaid Services, and then receive a score from the Congressional Budget Office. "That's a lot of work to be done in 18 days," he said. Davis added, however, that he is "optimistic that the RESULTS Act will get passed in 2026" and that Congress will pass a temporary delay as long as the RESULTS Act is making progress toward passage.

Show 5102550100 per page